Innate Pharma
IPHA

Innate Pharma (IPHA) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
BTIGMaintainedBuy$9.00Sep 17, 2026
BTIGMaintainedBuy$9.00 from $8.00Aug 12, 2026
HC Wainwright & Co.MaintainedBuy$7.00 from $5.00Aug 10, 2026
HC Wainwright & Co.MaintainedBuy$5.00Apr 7, 2026
BTIGInitiated CoverageBuy$8.00Mar 12, 2026
BTIGMaintainedBuy$8.00Oct 29, 2025
HC Wainwright & Co.UpgradedNeutral → Buy$5.00Oct 29, 2025
HC Wainwright & Co.DowngradedBuy → Neutral—Sep 18, 2025
Leerink PartnersDowngradedOutperform → Market Perform$2.00 from $10.00Sep 18, 2025
HC Wainwright & Co.MaintainedBuy$11.00 from $11.50Apr 24, 2025
HC Wainwright & Co.MaintainedBuy$11.50Mar 28, 2025
HC Wainwright & Co.MaintainedBuy$11.50Feb 6, 2025
HC Wainwright & Co.MaintainedBuy$11.50Jan 17, 2025
HC Wainwright & Co.MaintainedBuy$11.50Dec 9, 2024
HC Wainwright & Co.MaintainedBuy$11.50Nov 15, 2024
HC Wainwright & Co.MaintainedBuy$11.50Nov 12, 2024
HC Wainwright & Co.MaintainedBuy$11.50Sep 13, 2024
HC Wainwright & Co.MaintainedBuy$11.50Jun 12, 2024
HC Wainwright & Co.MaintainedBuy$11.50May 15, 2024
HC Wainwright & Co.MaintainedBuy$11.50Apr 11, 2024

Frequently asked questions

  • What is the latest analyst rating on IPHA?

    On Sep 17, 2026, BTIG maintained Innate Pharma at Buy with a price target of $9.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.